ESC 365 - ATTR-ACT Trial - Efficacy and Safety of Tafamidis in Transthyretin Amyloid Cardiomyopathy

ESC Premium Access

ATTR-ACT Trial - Efficacy and Safety of Tafamidis in Transthyretin Amyloid Cardiomyopathy

Session: Hot Line Session 3

Topic: Neurologic Disorders and Heart Disease

Speaker: Professor C. Rapezzi (Ferrara, IT)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Claudio Rapezzi

University of Ferrara, Ferrara (Italy)

29 presentations

3 followers

19 more presentations in this session

Opening question - ATTR-ACT Trial.

Discussant review - ATTR-ACT.

Speaker: Professor J. George (Rehovot, IL)

Questions from the audience and discussion.

Concluding question - ATTR-ACT Trial.

Opening question - COMMANDER HF.

Access the full session

Hot Line Session 3

Speakers: Professor C. Rapezzi, Professor J. George

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources